Prosecution Insights
Last updated: April 17, 2026
Application No. 18/640,214

METHODS OF FORMING AN ENCAPSULATED CORE MATERIAL, AN ENCAPSULATED MATERIAL, COMPOSITIONS USES THEREOF

Non-Final OA §DP
Filed
Apr 19, 2024
Examiner
GEMBEH, SHIRLEY V
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
unknown
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
2y 8m
To Grant
97%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allow Rate
1014 granted / 1606 resolved
+3.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
42 currently pending
Career history
1648
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
39.0%
-1.0% vs TC avg
§102
18.2%
-21.8% vs TC avg
§112
15.1%
-24.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1606 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-20 are pending and under examination in this office action. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-20 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 - 30 of U.S. Patent 12,145,120.. Although the conflicting claims are not identical, they are not patentably distinct from each other. The reasons are as follows: · The claims of the patent refers to method of forming an encapsulated core material, the method comprising: providing an interfacial fluid and providing a host fluid, the interfacial fluid being layered on the host fluid; dispensing a core material from a distance above the interfacial fluid layer; and passing the dispensed core material through the interfacial fluid and into the host fluid such that the interfacial fluid forms a shell around the core material, thereby forming the encapsulated core material and the claims of the instant claims refer to a method of forming an encapsulated core material, comprising: providing an interfacial material layered on a host fluid; dispensing a core material onto the interfacial material; interfacially trapping the core material in the interfacial material; and forming a shell of interfacial material around the interfacially-trapped core material that protects the core and forms the encapsulated core material. · The method recited in the claims are either anticipatory or obvious of each other. In view of the foregoing, the patented claims and the current application claims are obvious variations. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHIRLEY V GEMBEH whose telephone number is (571)272-8504. The examiner can normally be reached M-F 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A. Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHIRLEY V GEMBEH/Primary Examiner, Art Unit 1615 2/25/26
Read full office action

Prosecution Timeline

Apr 19, 2024
Application Filed
Feb 25, 2026
Examiner Interview (Telephonic)
Feb 26, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599566
TITANIUM DIOXIDE FREE WHITE FILM COATING COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594314
Process and Apparatus for Production of a Granular Cannabinoid Material Essentially Soluble in Aqueous Medium
2y 5m to grant Granted Apr 07, 2026
Patent 12582146
ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, BLOOD PRESSURE-LOWERING AGENT, AND BEVERAGES AND FOOD PRODUCTS
2y 5m to grant Granted Mar 24, 2026
Patent 12582689
USE OF TERPENOIDS IN THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
2y 5m to grant Granted Mar 24, 2026
Patent 12582690
Compositions for preventing or treating cancer comprising extracts of Rubus longisepalus var. tozawai (Nakai) T.B.Lee
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
97%
With Interview (+33.6%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 1606 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month